Skip Ribbon Commands
Skip to main content

Title

How Should HIV Vaccine Efficacy Trials Be Conducted?

Authors

Kegeles SM, Johnson MO, Strauss RP

Network Affiliation

Other

Organization

 

Journal Name

AIDS Education and Prevention

Publication Date

12/1/2006

PubMed Search

http://www.ncbi.nlm.nih.gov/pubmed/17166081

Link to full-text

http://www.atypon-link.com/doi/abs/10.1521/aeap.2006.18.6.560

PMID

17166081

Abstract

Developing an effective vaccine remains a critical long-term approach to HIV prevention. Every efficacy trial should be responsive to the concerns of participating communities because the successful development of an HIV preventive vaccine will require long-term involvement of people who have been marginalized and who distrust the government and biomedical research. Using qualitative interviews and purposive sampling, we elicited recommendations regarding how vaccine efficacy trials should be conducted from 90 members of communities that have been disproportionately affected by HIV/AIDS: injection drug users, gay men, and African Americans. The most common recommendation was for complete disclosure of all aspects of the trial. Other themes included participant and community education, who to include in trials, preventing harm, trust, community involvement, researcher attributes, and respect for participants. Developing positive, respectful and collaborative experiences with community members will facilitate vaccine research because negative experiences and unfavorable community reactions can greatly impede success in future trials.

Keywords

 

Topic

Racial Disparities; Recruitment & Retention

Attachments

Created at 11/18/2010 11:16 AM by Mooney, Jessica L
Last modified at 11/19/2010 10:44 AM by Mooney, Jessica L